We are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.

Leading researchers explain how the COVID-19 pandemic has spurred research on wearables, genomic surveillance, behavioral interventions and drug discovery.

Restoration of visual function in degenerative retinal disease may be an attainable goal, thanks to advances in cell-based therapy, gene therapy, and prosthetics. This Review discusses the most promising strategies that will probably reach clinical use in the next decade.

The authors propose a new conceptual model of critical illness that moves away from the current syndrome-based framework in favor of more precise biological descriptors—spurred by mounting translational evidence and insights from Coronavirus Disease 2019 (COVID-19) research.

An ecological analysis of 326 cities in 9 countries across Latin America found that changes in ambient temperature have a substantial contribution to all-cause mortality, with small increases in extreme heat associated with steep increases in mortality risk.

Multiomics analysis of tumor samples from the phase 1b GO30140 and phase 3 IMbrave150 trials reveals baseline immune and genetic features that might identify patients with advanced hepatocellular carcinoma who will benefit from atezolizumab and bevacizumab combination therapy.

An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy.

In a phase 2a clinical trial in patients with nonalcoholic steatohepatitis, dual inhibition of sodium–glucose cotransporters 1 and 2 with 150 mg of licogliflozin led to reductions in serum alanine aminotranferase levels.

A new approach to pandemic and epidemic intelligence is needed that includes modern approaches to surveillance and risk assessment, as well as improved trust and cooperation between stakeholders and society.

In a phase 3 study, the diabetes drug tirzepatide brought about substantial and sustained weight reduction in adults with obesity.

Improved screening, novel therapies and a focus on health equity can reduce cancer mortality by 50% in the next 25 years, but these must be underpinned by an investment in basic, translational and clinical research, along with open data.

Patients with HER2-low metastatic breast cancer are a historically overlooked group, but a phase 3 trial reveals trastuzumab deruxtecan as a new treatment option that prolongs survival.